Gilead and Merck announce positive Phase 2 data for weekly oral HIV combination regimen of islatravir and lenacapavir.
Gilead Sciences and Merck & Co. announced positive Phase 2 data on a weekly oral HIV combination regimen, consisting of Merck's islatravir and Gilead's lenacapavir, which maintained viral suppression. This combination therapy has the potential to be the first weekly oral HIV treatment.
March 06, 2024
3 Articles